A potent, non-selective agonist for cannabinoid (CB) receptors (Ki = 0.6 - 5.0 and 0.7 - 2.6 nM for CB1 and CB2 respectively; EC50 = 0.2, 0.3 and 5 nM for CB1, CB2 and GRP55 respectively). Often used in reference or control trials in CB research and the effects are robust in both behavioral tests and receptor binding assays.
A potent, non-selective agonist for cannabinoid (CB) receptors (Ki = 0.6 - 5.0 and 0.7 - 2.6 nM for CB1 and CB2 respectively; EC50 = 0.2, 0.3 and 5 nM for CB1, CB2 and GRP55 respectively). Often used in reference or control trials in CB research and the effects are robust in both behavioral tests and receptor binding assays.
Biochem/physiol Actions
Primary Target CB receptors
Target Ki: 0.6 - 5.0 and 0.7 - 2.6 nM for CB₁ and CB₂ respectively.
Warning
Toxicity: Standard Handling (A)
Physical form
Supplied in methanol.
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Wiley, J., et al. 1995. Neuropharmacology.34, 669. Griffin, G., et al. 1998. J. Pharmacol. Exp. Ther.285, 553.
Thomas, B., et al. 1998. J. Pharmacol. Exp. Ther.285, 285. Avdesh, A., et al. 2012. Psychopharmacology (Berl).220, 405.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
CP 55,940 is a potent synthetic bicyclic cannabinoid analog that has been used in a number of studies as a radioligand for the cannabinoid receptor. This compound shares behavioral and biochemical properties with naturally occurring cannabinoids such as delta 9-THC.
The Journal of pharmacology and experimental therapeutics, 285(1), 285-292 (1998-05-16)
To further characterize neuronal cannabinoid receptors, we compared the ability of known and novel cannabinoid analogs to compete for receptor sites labeled with either [3H]SR141716A or [3H]CP-55,940. These efforts were also directed toward extending the structure-activity relationships for cannabinoid agonists
There are inconsistent reports on the effects of cannabinoid agonists on prepulse inhibition of the startle reflex (PPI) with increases, decreases, and no effects. It has been hypothesized that the conflicting observations may be as a result of modulation of
The Journal of pharmacology and experimental therapeutics, 285(2), 553-560 (1998-05-15)
Cannabinoid receptors are members of the superfamily of G protein-coupled receptors. Their activation has previously been shown to stimulate guanosine 5'-O-(3-[35S]thio)-triphosphate ([35S]GTP gamma S) binding in a range of brain regions using both membrane preparations and autoradiography. This study evaluates
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
